Seranova Bio

Executive Summary

Seranova Bio leverages naturally occurring autoantibody profiles as a form of 'natural clinical trial' to identify new antibody targets for therapeutic development. Their proprietary platform collects and analyzes autoantibody data from patients, uncovering associations between specific autoantibodies and disease outcomes. This approach reduces risk by using real-world immune responses as evidence, potentially enabling more efficient target discovery. Based in Cambridge, MA, and founded in 2021, the company is in an early stage with no disclosed pipeline or funding. However, its innovative strategy positions it well to address unmet needs in autoimmune and other diseases.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Announcement80% success
• 2027First Major Pharma Partnership60% success
• Q3 2026Publication of Key Validation Data70% success